---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-022898"
form_type: "8-K"
ticker: "CURX"
cik: "0002025942"
company_name: "Curanex Pharmaceuticals Inc"
filed_at: "2026-05-14T13:15:35+00:00"
generated_at: "2026-05-14T13:17:40.098399+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Curanex completes key Phyto-N milestones; plans Q4 2026 IND for ulcerative colitis

## Summary
- Completed GMP pilot-scale batch of Phyto-N in February 2026 to support IND-enabling studies.
- 28-day dose-range finding toxicology study in rats and dogs showed no adverse findings at any dose.
- Expanded pipeline to include cancer cachexia; global market estimated at $2.54B in 2024.
- Cash and equivalents of ~$4.0M as of March 31, 2026, sufficient for near-term development activities.
- Targeting Q4 2026 IND submission for ulcerative colitis; Phase I trial to follow FDA review.

## SEC filing metadata
- accession: 0001493152-26-022898
- form_type: 8-K
- ticker: CURX
- cik: 0002025942
- company_name: Curanex Pharmaceuticals Inc
- filed_at: 2026-05-14T13:15:35+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/2025942/000149315226022898/0001493152-26-022898-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/2025942/000149315226022898/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-022898
- JSON: https://secwatch.observer/filing/0001493152-26-022898.json
- Plain text: https://secwatch.observer/filing/0001493152-26-022898.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.